Synopsis
Synopsis
0
VMF
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Galantamin
2. Galantamine
3. Galanthamine
4. Galanthamine Hydrobromide
5. Lycoremine
6. Nivalin
7. Nivaline
8. Razadyne
9. Reminyl
1. Galanthamine Hydrobromide
2. 1953-04-4
3. Reminyl
4. Nivalin
5. Nivaline
6. Razadyne
7. Lycoremine Hydrobromide
8. Jilkon Hydrobromide
9. Galanthamine (hydrobromide)
10. Galanthamine Hbr
11. Tamilin
12. 193146-85-9
13. Mj4ptd2vvw
14. 5n4sa4kqx9
15. (-)-galantamine Hydrobromide
16. (+/-)-galantamine Hydrobromide
17. (+/-)-galanthamine Hydrobromide
18. Galantamine Hydrobromide (racemic)
19. Galantamine Hydrobromide, (+/-)-
20. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol;hydrobromide
21. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
22. Razadyne Er
23. Reminyl (tn)
24. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azoniatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol;bromide
25. (4as,6r,8as)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6h-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol Hydrobromide
26. Galanthaminehydrobromide
27. 1953-04-4 (hbr); 1953-04-4 (free Base).
28. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6(17),7,9,15-tetraen-14-ol Hydrobromide
29. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol Hydrobromide
30. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide (1:1), (4ar,6s,8ar)-rel-
31. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide (1:1), (4as,6r,8as)-
32. Smr000449267
33. Sr-01000597844
34. Nivaline (pharmaceutical)
35. C17h22brno3
36. Anti-alzheimer
37. Sr-05000001783
38. Nivalin;razadyne
39. Galantamine Hydrobromide [usan]
40. Reminyl Xl
41. Jilcon Hydrobromide
42. Razadyne (tn)
43. Prestwick_236
44. Einecs 217-780-5
45. Galanthamine Hydrobromide From Lycoris Sp.
46. Mfcd00067672
47. Unii-mj4ptd2vvw
48. Unii-5n4sa4kqx9
49. 1953-04-4 Unlabeled
50. Chembl1555
51. Galanthamine-d3 Hydrobromide
52. Mls000758283
53. Mls001401401
54. Galanthamine Hydrobromide,(s)
55. Schembl177993
56. Spectrum1501202
57. Hms1569f18
58. Hms1921p21
59. Hy-a0009
60. Galantamine Hydrobromide (jan/usp)
61. Ac-469
62. Ccg-38829
63. Galantamine Hydrobromide [mi]
64. Galantamine Hydrobromide [usan:usp]
65. S1339
66. Galantamine Hydrobromide [jan]
67. Galanthamine-o-methyl-d3 Hydrobromide
68. Akos007930166
69. Akos015960209
70. Cs-0378
71. Fd10095
72. Galantamine Hydrobromide [hsdb]
73. Nc00061
74. Galantamine Hydrobromide [mart.]
75. Galantamine Hydrobromide [vandf]
76. Galantamine Hydrobromide [usp-rs]
77. Galantamine Hydrobromide [who-dd]
78. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4as,6r,8as)-
79. As-12155
80. Gp-37267
81. G0293
82. Galantamine Hydrobromide [orange Book]
83. D02173
84. Galantamine Hydrobromide [ep Monograph]
85. Galantamine Hydrobromide [usp Monograph]
86. Galantamine Hydrobromide Racemic [usp-rs]
87. 953g044
88. A866857
89. A903748
90. R-113675
91. Sr-01000597844-1
92. Sr-01000597844-5
93. Sr-05000001783-3
94. Q47495772
95. Z1558572528
96. Galanthamine Hydrobromide From Lycoris Sp., >=94% (tlc)
97. (4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol Hydrobromide
98. (4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-olhydrobromide
99. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, Hydrobromide
100. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-d3-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
101. 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
102. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hbr (1:1), (4as,6r,8as)-
103. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hbr, (4as,6r,8as)-
104. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4a.alpha.,6.beta.,8ar*)-
105. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4aalpha,6beta,8ar*)-
1. Galantamine
2. Galanthamine Hydrobromide
3. Lycoremin
4. Lycoremine
5. Nivalin
6. Razadyne
7. Reminyl
8. Galanthamine
Molecular Weight | 368.3 g/mol |
---|---|
Molecular Formula | C17H22BrNO3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 1 |
Exact Mass | 367.07831 g/mol |
Monoisotopic Mass | 367.07831 g/mol |
Topological Polar Surface Area | 41.9 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 440 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Galantamine hydrobromide |
PubMed Health | Galantamine (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | Galantamine hydrobromide is a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro [3a,3,2-ef][2]benzazepin-6-ol hydrobromide.... |
Active Ingredient | Galantamine hydrobromide |
Dosage Form | Tablet; Capsule, extended release; Solution |
Route | oral; Oral |
Strength | eq 4mg base; 8mg; eq 12mg base; 4mg; 4mg/ml; 12mg; eq 16mg base; eq 24mg base; eq 8mg base |
Market Status | Tentative Approval; Prescription |
Company | Ranbaxy; Apotex; Aurobindo Pharma; Sun Pharm Inds; Sandoz; Sun Pharma Global; Roxane; Watson Labs; Teva Pharms; Zydus Pharms Usa; Dr Reddys Labs; Mylan; Impax Labs; Barr |
2 of 4 | |
---|---|
Drug Name | Razadyne |
Drug Label | RAZADYNE ER/RAZADYNE (galantamine hydrobromide) is galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS ,6R,8aS )-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H... |
Active Ingredient | Galantamine hydrobromide |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 4mg base; eq 12mg base; 4mg/ml; eq 8mg base |
Market Status | Prescription |
Company | Janssen Pharms |
3 of 4 | |
---|---|
Drug Name | Galantamine hydrobromide |
PubMed Health | Galantamine (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | Galantamine hydrobromide is a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro [3a,3,2-ef][2]benzazepin-6-ol hydrobromide.... |
Active Ingredient | Galantamine hydrobromide |
Dosage Form | Tablet; Capsule, extended release; Solution |
Route | oral; Oral |
Strength | eq 4mg base; 8mg; eq 12mg base; 4mg; 4mg/ml; 12mg; eq 16mg base; eq 24mg base; eq 8mg base |
Market Status | Tentative Approval; Prescription |
Company | Ranbaxy; Apotex; Aurobindo Pharma; Sun Pharm Inds; Sandoz; Sun Pharma Global; Roxane; Watson Labs; Teva Pharms; Zydus Pharms Usa; Dr Reddys Labs; Mylan; Impax Labs; Barr |
4 of 4 | |
---|---|
Drug Name | Razadyne |
Drug Label | RAZADYNE ER/RAZADYNE (galantamine hydrobromide) is galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS ,6R,8aS )-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H... |
Active Ingredient | Galantamine hydrobromide |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 4mg base; eq 12mg base; 4mg/ml; eq 8mg base |
Market Status | Prescription |
Company | Janssen Pharms |
Nootropic Agents
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)
Cholinesterase Inhibitors
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)
Parasympathomimetics
Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)
Capital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-12-05
Pay. Date : 2012-11-08
DMF Number : 18112
Submission : 2005-02-23
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-08-24
Pay. Date : 2015-08-17
DMF Number : 17863
Submission : 2004-12-01
Status : Active
Type : II
Certificate Number : CEP 2011-011 - Rev 02
Issue Date : 2024-10-21
Type : Chemical
Substance Number : 2366
Status : Valid
Registration Number : 230MF10065
Registrant's Address : No. 1, Nan-Ke 8th Road, Shan-Hua, Tainan 741014, Taiwan
Initial Date of Registration : 2018-05-15
Latest Date of Registration :
NDC Package Code : 65129-1332
Start Marketing Date : 2013-09-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Hyundai Pharmaceutical Co., Ltd.
Registration Date : 2021-10-12
Registration Number : 20211012-209-J-1119
Manufacturer Name : ScinoPharm Taiwan, Ltd.
Manufacturer Address : No. 1, Nan-ke 8th Road, Shan-Hua, Tainan 741014, Taiwan
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27564
Submission : 2013-12-30
Status : Active
Type : II
NDC Package Code : 65129-1113
Start Marketing Date : 2004-04-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17972
Submission : 2005-01-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26643
Submission : 2012-11-26
Status : Active
Type : II
Certificate Number : CEP 2023-389 - Rev 00
Issue Date : 2024-06-19
Type : Chemical
Substance Number : 2366
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18114
Submission : 2005-02-22
Status : Inactive
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2014-12-05
Pay. Date : 2012-11-08
DMF Number : 18112
Submission : 2005-02-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18152
Submission : 2005-03-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18045
Submission : 2005-01-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15384
Submission : 2001-05-08
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14425
Submission : 1999-09-29
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-08-24
Pay. Date : 2015-08-17
DMF Number : 17863
Submission : 2004-12-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18114
Submission : 2005-02-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17967
Submission : 2005-01-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17972
Submission : 2005-01-05
Status : Active
Type : II
Galantamine Hydrobromide Ph.Eur
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Survey no. 52,53,58,59,61 to 78,127&128, Pydibhimanvaram Village &Sy.No. 1,2,4t0...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2020-06-27
Date Granted : 2005-11-08
Brand Name : REMINYL
Patent Number : 2310950
Filing Date : 2000-06-27
Strength per Unit : 4 mg/ml
Dosage Form : Oral Solution
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2020-06-27
Date Granted : 2005-11-08
Patent Expiration Date : 2020-06-27
Date Granted : 2002-10-15
Brand Name : REMINYL
Patent Number : 2310926
Filing Date : 2000-06-27
Strength per Unit : 4 mg/ml
Dosage Form : Oral Solution
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2020-06-27
Date Granted : 2002-10-15
Patent Expiration Date : 2020-06-27
Date Granted : 2002-10-15
Brand Name : REMINYL ER
Patent Number : 2310926
Filing Date : 2000-06-27
Strength per Unit : 8 mg
Dosage Form : Extended Release Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2020-06-27
Date Granted : 2002-10-15
Patent Expiration Date : 2019-12-20
Date Granted : 2006-12-19
Brand Name : REMINYL ER
Patent Number : 2358062
Filing Date : 1999-12-20
Strength per Unit : 8 mg
Dosage Form : Extended Release Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2019-12-20
Date Granted : 2006-12-19
Patent Expiration Date : 2020-06-27
Date Granted : 2005-11-08
Brand Name : REMINYL ER
Patent Number : 2310950
Filing Date : 2000-06-27
Strength per Unit : 8 mg
Dosage Form : Extended Release Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2020-06-27
Date Granted : 2005-11-08
Patent Expiration Date : 2020-06-27
Date Granted : 2002-10-15
Brand Name : REMINYL ER
Patent Number : 2310926
Filing Date : 2000-06-27
Strength per Unit : 16 mg
Dosage Form : Extended Release Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2020-06-27
Date Granted : 2002-10-15
Patent Expiration Date : 2019-12-20
Date Granted : 2006-12-19
Brand Name : REMINYL ER
Patent Number : 2358062
Filing Date : 1999-12-20
Strength per Unit : 16 mg
Dosage Form : Extended Release Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2019-12-20
Date Granted : 2006-12-19
Patent Expiration Date : 2020-06-27
Date Granted : 2005-11-08
Brand Name : REMINYL ER
Patent Number : 2310950
Filing Date : 2000-06-27
Strength per Unit : 16 mg
Dosage Form : Extended Release Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2020-06-27
Date Granted : 2005-11-08
Patent Expiration Date : 2020-06-27
Date Granted : 2002-10-15
Brand Name : REMINYL ER
Patent Number : 2310926
Filing Date : 2000-06-27
Strength per Unit : 24 mg
Dosage Form : Extended Release Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2020-06-27
Date Granted : 2002-10-15
Patent Expiration Date : 2019-12-20
Date Granted : 2006-12-19
Brand Name : REMINYL ER
Patent Number : 2358062
Filing Date : 1999-12-20
Strength per Unit : 24 mg
Dosage Form : Extended Release Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2019-12-20
Date Granted : 2006-12-19
REF. STANDARDS & IMPURITIES
Galantamine synthetic for system suitability
CAS Number : 1953-04-4
Quantity Per Vial : 5 mg
Sale Unit : 1
Order Code : Y0001191
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C
CAS Number : 1953-04-4
Quantity Per Vial : 10 mg
Sale Unit : 1
Order Code : Y0001201
Batch No : 1
Price (€) : 79
Storage : +5°C ± 3°C
Galantamine natural for system suitability
CAS Number : 1953-04-4
Quantity Per Vial : 10 mg
Sale Unit : 1
Order Code : Y0001190
Batch No : 1
Price (€) : 79
Storage : +5°C ± 3°C
CAS Number : 1953-04-4
Quantity Per Vial : 10 mg
Sale Unit : 1
Order Code : Y0001279
Batch No : 1
Price (€) : 79
Storage : +5°C ± 3°C
ABOUT THIS PAGE
28
PharmaCompass offers a list of Galantamine Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Galantamine Hydrobromide manufacturer or Galantamine Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Galantamine Hydrobromide manufacturer or Galantamine Hydrobromide supplier.
PharmaCompass also assists you with knowing the Galantamine Hydrobromide API Price utilized in the formulation of products. Galantamine Hydrobromide API Price is not always fixed or binding as the Galantamine Hydrobromide Price is obtained through a variety of data sources. The Galantamine Hydrobromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Galanthamine hydrobromide from Lycoris sp. manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Galanthamine hydrobromide from Lycoris sp., including repackagers and relabelers. The FDA regulates Galanthamine hydrobromide from Lycoris sp. manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Galanthamine hydrobromide from Lycoris sp. API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Galanthamine hydrobromide from Lycoris sp. manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Galanthamine hydrobromide from Lycoris sp. supplier is an individual or a company that provides Galanthamine hydrobromide from Lycoris sp. active pharmaceutical ingredient (API) or Galanthamine hydrobromide from Lycoris sp. finished formulations upon request. The Galanthamine hydrobromide from Lycoris sp. suppliers may include Galanthamine hydrobromide from Lycoris sp. API manufacturers, exporters, distributors and traders.
click here to find a list of Galanthamine hydrobromide from Lycoris sp. suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Galanthamine hydrobromide from Lycoris sp. DMF (Drug Master File) is a document detailing the whole manufacturing process of Galanthamine hydrobromide from Lycoris sp. active pharmaceutical ingredient (API) in detail. Different forms of Galanthamine hydrobromide from Lycoris sp. DMFs exist exist since differing nations have different regulations, such as Galanthamine hydrobromide from Lycoris sp. USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Galanthamine hydrobromide from Lycoris sp. DMF submitted to regulatory agencies in the US is known as a USDMF. Galanthamine hydrobromide from Lycoris sp. USDMF includes data on Galanthamine hydrobromide from Lycoris sp.'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Galanthamine hydrobromide from Lycoris sp. USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Galanthamine hydrobromide from Lycoris sp. suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Galanthamine hydrobromide from Lycoris sp. Drug Master File in Japan (Galanthamine hydrobromide from Lycoris sp. JDMF) empowers Galanthamine hydrobromide from Lycoris sp. API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Galanthamine hydrobromide from Lycoris sp. JDMF during the approval evaluation for pharmaceutical products. At the time of Galanthamine hydrobromide from Lycoris sp. JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Galanthamine hydrobromide from Lycoris sp. suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Galanthamine hydrobromide from Lycoris sp. Drug Master File in Korea (Galanthamine hydrobromide from Lycoris sp. KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Galanthamine hydrobromide from Lycoris sp.. The MFDS reviews the Galanthamine hydrobromide from Lycoris sp. KDMF as part of the drug registration process and uses the information provided in the Galanthamine hydrobromide from Lycoris sp. KDMF to evaluate the safety and efficacy of the drug.
After submitting a Galanthamine hydrobromide from Lycoris sp. KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Galanthamine hydrobromide from Lycoris sp. API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Galanthamine hydrobromide from Lycoris sp. suppliers with KDMF on PharmaCompass.
A Galanthamine hydrobromide from Lycoris sp. CEP of the European Pharmacopoeia monograph is often referred to as a Galanthamine hydrobromide from Lycoris sp. Certificate of Suitability (COS). The purpose of a Galanthamine hydrobromide from Lycoris sp. CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Galanthamine hydrobromide from Lycoris sp. EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Galanthamine hydrobromide from Lycoris sp. to their clients by showing that a Galanthamine hydrobromide from Lycoris sp. CEP has been issued for it. The manufacturer submits a Galanthamine hydrobromide from Lycoris sp. CEP (COS) as part of the market authorization procedure, and it takes on the role of a Galanthamine hydrobromide from Lycoris sp. CEP holder for the record. Additionally, the data presented in the Galanthamine hydrobromide from Lycoris sp. CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Galanthamine hydrobromide from Lycoris sp. DMF.
A Galanthamine hydrobromide from Lycoris sp. CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Galanthamine hydrobromide from Lycoris sp. CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Galanthamine hydrobromide from Lycoris sp. suppliers with CEP (COS) on PharmaCompass.
A Galanthamine hydrobromide from Lycoris sp. written confirmation (Galanthamine hydrobromide from Lycoris sp. WC) is an official document issued by a regulatory agency to a Galanthamine hydrobromide from Lycoris sp. manufacturer, verifying that the manufacturing facility of a Galanthamine hydrobromide from Lycoris sp. active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Galanthamine hydrobromide from Lycoris sp. APIs or Galanthamine hydrobromide from Lycoris sp. finished pharmaceutical products to another nation, regulatory agencies frequently require a Galanthamine hydrobromide from Lycoris sp. WC (written confirmation) as part of the regulatory process.
click here to find a list of Galanthamine hydrobromide from Lycoris sp. suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Galanthamine hydrobromide from Lycoris sp. as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Galanthamine hydrobromide from Lycoris sp. API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Galanthamine hydrobromide from Lycoris sp. as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Galanthamine hydrobromide from Lycoris sp. and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Galanthamine hydrobromide from Lycoris sp. NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Galanthamine hydrobromide from Lycoris sp. suppliers with NDC on PharmaCompass.
Galanthamine hydrobromide from Lycoris sp. Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Galanthamine hydrobromide from Lycoris sp. GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Galanthamine hydrobromide from Lycoris sp. GMP manufacturer or Galanthamine hydrobromide from Lycoris sp. GMP API supplier for your needs.
A Galanthamine hydrobromide from Lycoris sp. CoA (Certificate of Analysis) is a formal document that attests to Galanthamine hydrobromide from Lycoris sp.'s compliance with Galanthamine hydrobromide from Lycoris sp. specifications and serves as a tool for batch-level quality control.
Galanthamine hydrobromide from Lycoris sp. CoA mostly includes findings from lab analyses of a specific batch. For each Galanthamine hydrobromide from Lycoris sp. CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Galanthamine hydrobromide from Lycoris sp. may be tested according to a variety of international standards, such as European Pharmacopoeia (Galanthamine hydrobromide from Lycoris sp. EP), Galanthamine hydrobromide from Lycoris sp. JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Galanthamine hydrobromide from Lycoris sp. USP).